CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 66 enrolled
Drug / intervention
GSK1292263 +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01128621
NCT01128621Phase 2Completed
CompareCT.gov

A Study in Type 2 Diabetic Subjects on Stable Metformin Therapy to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Co-administering Single and Multiple Oral Doses of GSK1292263

GlaxoSmithKline·interventional·Posted May 24, 2010·Updated Oct 16, 2017

In Brief

A Phase 2 clinical trial evaluating GSK1292263, GSK1292263 matching placebo, and 1 other intervention for Diabetes Mellitus, Type 2. Completed, enrolled 66 participants across 2 sites.

Detailed Summary

A study in type 2 diabetic subjects on stable metformin therapy to investigate the safety, tolerability, pharmacokinetics and pharmacodynamics of co-administering single and multiple oral doses of GSK1292263

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsDiabetes Mellitus, Type 2
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
20102011201220132014201520162017201820192020202120222023202420252026
First PostedMay 24, 2010
Enrollment StartNov 23, 2009
Primary CompletionApr 12, 2010
TodayJul 2, 2026
Enrollment to primary: 5 monthsPosted 16.1 years ago

Interventions

GSK1292263drug

Tablet

GSK1292263 matching placebodrug

Tablet

Sitagliptindrug

Tablet